leukemia

(redirected from acute promyelocytic leukemia)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for leukemia

References in periodicals archive ?
Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis.
in correlation with all clinical data, confirmed a persistent disease state of acute promyelocytic leukemia.
Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia.
Coverage of the Acute Promyelocytic Leukemia pipeline on the basis of route of administration and molecule type.
Acute promyelocytic leukemia (APL), a M3 type of AML based on French-American-British (FAB) classification, is uniquely sensitive to undergo terminal differentiation by differentiation-inducing agents, such as retinoids (i.
TRISENOX is indicated for the induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
Tretinoin Capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t (15;17) translocation and/or the presence of the PML/RARalpha gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated.
The company has four drug programs in clinical development: Tamibarotene, INNO-406, INNO-206, and INNO-305, for the treatment of acute promyelocytic leukemia, chronic myelogenous leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively.
CTI)(Nasdaq: CTIC; Nuovo Mercato) announced today that a phase III study of TRISENOX consolidation treatment in patients with newly diagnosed acute promyelocytic leukemia (APL) completed enrollment with approximately 500 patients.
CytRx is currently conducting a Phase 2b global clinical trial with tamibarotene as a first-line treatment for non-small-cell lung cancer (NSCLC) and a Phase 2 clinical trial with tamibarotene as a treatment for acute promyelocytic leukemia (APL).
Having been healthy all her life, in 2004 Christine was diagnosed with Acute Promyelocytic Leukemia (APL), a rare type of leukemia.
Nippon Shinyaku) has launched TRISENOX(R) (arsenic trioxide) in Japan after receiving pricing approval from the Japanese Ministry of Health to market the drug for patients with relapsed or refractory acute promyelocytic leukemia (APL).
CytRx also is conducting a Phase 2 clinical trial with tamibarotene as a treatment for acute promyelocytic leukemia (APL).
CALGB and NCI Report Improved Survival in Newly Diagnosed Adult Patients with Acute Promyelocytic Leukemia (APL) in Study Using TRISENOX --
Full browser ?